Two endpoints, face and body, measured separately — because in vitiligo where the pigment returns matters as much as how much.
Ninety percent of trials fail. A platform claiming 90% accuracy at predicting outcomes is reporting its own figure — which is the part to hold onto.
The drug worked. Two patients developed a rare cancer, the same one that killed a competitor’s programme, and working was not enough.
Deaths were 7.2% in the stop group and 7.9% in the continue group over three years. LDL rose 50%. Both facts are the result, and reconciling them is the point.
A 102% premium paid to the last bidder standing. The filings show five other parties walked away before Vertex raised its offer three times.
Thousands of independent primary-care practices sit outside insurance networks, unreachable by employers one contract at a time. Aligned aggregates them under one agreement.
The scientist who showed CAR-T could drive lupus into remission has co-founded a company trying to achieve the same reset without cells — with $65 million and three approaches.
The same protein measured in blood tells you nothing. Where C3 is made inside the tumour is what decides whether checkpoint inhibitors work.
Fifty-two injections a year instead of 365. NICE recommended it on equivalence rather than superiority — because for insulin, the same control with fewer injections is the improvement.
The lateral septum sits between knowing a reward exists and feeling compelled to pursue it. It is dense with GLP-1 receptors — which may explain why these drugs quiet cravings beyond food.
One drug delivers DNA damage to the tumour; the other blocks the repair crew. The combination also tripped an innate immune alarm the researchers were not primarily aiming at.
Fat exposure raised OPA1 in male mice and not females. An approved obesity drug then worked much more weakly in OPA1-deficient females — which is the finding with practical teeth.